Progyny (PGNY) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Apr, 2026Executive summary
The annual meeting will be held virtually on May 21, 2026, with stockholders able to participate online and vote on key proposals.
Proxy materials and the annual report are available online, with voting accessible via internet, phone, or mail.
Only stockholders of record as of March 27, 2026, are eligible to vote.
Voting matters and shareholder proposals
Proposals include electing three Class I directors, ratifying Ernst & Young LLP as auditor, approving executive compensation (say-on-pay), and amending the Certificate of Incorporation to eliminate certain supermajority voting requirements.
Shareholders will also vote on eliminating the default supermajority voting requirement for certain business combinations.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
The board consists of ten members divided into three classes with staggered three-year terms.
Eight directors are independent under Nasdaq standards; the CEO and Executive Chairman are not.
Board leadership includes an executive chairman and a lead independent director.
Committees include audit, compensation, and nominating/governance, all composed of independent directors.
Board and committees met regularly, with high attendance and executive sessions held.
Latest events from Progyny
- Votes will address director elections, auditor ratification, and governance amendments.PGNY
Proxy filing10 Apr 2026 - Key votes include director elections, auditor ratification, and reducing supermajority voting thresholds.PGNY
Proxy filing31 Mar 2026 - Strong utilization and new product launches drive growth amid stable competition and tech investment.PGNY
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026 - Stable growth, high retention, and new market expansion drive a positive long-term outlook.PGNY
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Record 2025 revenue and margin gains, with 2026 guidance projecting further growth.PGNY
Q4 202526 Feb 2026 - Q2 revenue up 9%, guidance cut 5%, with record margins and $100M added to share buybacks.PGNY
Q2 20242 Feb 2026 - Targets $2.4B+ revenue and 20% CAGR by 2028, fueled by new women's health products.PGNY
Investor Day 20242 Feb 2026 - Utilization rebounded after a Q1 dip, with strong membership growth and a favorable outlook.PGNY
Jefferies 2024 Global Healthcare Conference31 Jan 2026 - Q3 revenue up 2%, net income and margins down; new clients, services, and buybacks offset client loss risk.PGNY
Q3 202414 Jan 2026